Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Xeljanz | Tofacitinib | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
Kalydeco | Ivacaftor | Cystic Fibrosis, CFTR gating mutations | List with criteria/condition | Complete | ||
Arzerra | Ofatumumab | Chronic Lymphocytic Leukemia | Do not reimburse | Complete | ||
TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
Revolade | Eltrombopag | Thrombocytopenia associated with chronic hepatitis c infection | List with criteria/condition | Complete | ||
Afinitor | Everolimus | Subependymal giant cell astrocytoma associated with tuberous sclerosis complex | Do not list | Complete | ||
Firazyr | Icatibant | Hereditary angioedema | List with clinical criteria and/or conditions | Complete | ||
Actemra | Tocilizumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
Lucentis | Ranibizumab | Myopic choroidal neovascularisation | List with criteria/condition | Complete | ||
Signifor | Pasireotide diaspartate | Cushing’s disease | Do not list | Complete |